Table 3.

Baseline and maximum vascular conductance

Pharmacological Treatment	HC		MDD		Group (${\mathrm{\eta }}_{\text{p}}^2$)	Condition (${\mathrm{\eta }}_{\text{p}}^2$)	Drug (${\mathrm{\eta }}_{\text{p}}^2$)	Sex (${\mathrm{\eta }}_{\text{p}}^2$)	Group × Condition × Drug (${\mathrm{\eta }}_{\text{p}}^2$)
	Pre	Post	Pre	Post
Baseline					0.30 (0.01)	0.34 (<0.01)	<0.01 (0.14)	0.98 (0.0)	0.58 (0.02)
Control	0.21 ± 0.09	0.26 ± 0.15	0.26 ± 0.11	0.25 ± 0.10
l-NAME	0.19 ± 0.11	0.22 ± 0.08	0.12 ± 0.04	0.15 ± 0.07
Apocynin			0.16 ± 0.07	0.20 ± 0.07
l-NAME + apocynin			0.12 ± 0.04	0.19 ± 0.10
Maximum					0.19 (0.02)	0.35 (<0.01)	0.12 (0.06)	0.32 (0.03)	0.47 (0.03)
Control	1.96 ± 0.30	1.69 ± 0.91	1.75 ± 0.57	1.71 ± 0.50
l-NAME	1.50 ± 0.63	1.45 ± 0.49	1.48 ± 0.48	1.77 ± 0.64
Apocynin			1.46 ± 0.58	1.61 ± 0.30
l-NAME + apocynin			1.65 ± 0.69	1.81 ± 0.51

Values are means ± SD. Vascular conductance = flux/mean arterial pressure (perfusion units/mmHg). Data were analyzed using three-way, mixed-model, repeated-measures analysis of covariance; n = 10 HA (5 women), and n = 13 MDD (6 women). HA, healthy nondepressed adult; l-NAME, N^G-nitro-l-arginine methyl ester; MDD, major depressive disorder.